We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+35.36%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$378M
AUM Growth
+$3.5M
Cap. Flow
+$129M
Cap. Flow %
34.23%
Top 10 Hldgs %
57.24%
Holding
101
New
34
Increased
16
Reduced
11
Closed
39

Top Buys

Rank Stock Value
1
AUTL
Autolus Therapeutics
AUTL
+$15.7M
2
ROIV icon
Roivant Sciences
ROIV
+$14.9M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$14.5M
4
CABA icon
Cabaletta Bio
CABA
+$11.9M
5
IMVT icon
Immunovant
IMVT
+$11.1M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$11.8M
2
ACLX
Arcellx
ACLX
+$11M
3
MRUS
Merus
MRUS
+$10.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$10.3M
5
MRK icon
Merck
MRK
+$9.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
26
MoonLake Immunotherapeutics
MLTX
$1.64B
$4.55M 1.2%
90,647
-77,204
-46% -$4.19M
ANNX icon
27
Annexon
ANNX
$950M
$4.34M 1.15%
605,117
-1,983
-0.3% -$10.3K
FULC icon
28
Fulcrum Therapeutics
FULC
$243M
$3.84M 1.02%
407,108
+30,535
+8% +$273K
IDYA icon
29
IDEAYA Biosciences
IDYA
$3.47B
$3.83M 1.01%
+87,393
New +$3.76M
JSPR icon
30
Jasper Therapeutics
JSPR
$24.8M
$3.79M 1%
+129,211
New +$2.3M
AVDL
31
DELISTED
Avadel Pharmaceuticals
AVDL
$3.78M 1%
+223,660
New +$3.33M
IRON icon
32
Disc Medicine
IRON
$2.91B
$3.74M 0.99%
60,129
-65,300
-52% -$4.23M
TSHA icon
33
Taysha Gene Therapies
TSHA
$1.71B
$3.12M 0.83%
+1,087,785
New +$2.27M
ATXS
34
DELISTED
Astria Therapeutics
ATXS
$2.68M 0.71%
230,273
-626,679
-73% -$7.8M
SYRE icon
35
Spyre Therapeutics
SYRE
$8.7B
$2.36M 0.62%
62,253
-316,513
-84% -$9.17M
BBOT
36
BridgeBio Oncology
BBOT
$686M
$2.08M 0.55%
+200,000
New +$2.07M
EFTR
37
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$1.91M 0.51%
+132,793
New +$1.59M
NAMS icon
38
NewAmsterdam Pharma
NAMS
$3.7B
$1.9M 0.5%
+80,334
New +$1.63M
CGON icon
39
CG Oncology
CGON
$6.34B
$1.79M 0.47%
+40,723
New +$1.66M
ACHL
40
DELISTED
Achilles Therapeutics
ACHL
$1.73M 0.46%
+1,385,750
New +$1.49M
PRAX icon
41
Praxis Precision Medicines
PRAX
$8.77B
$1.64M 0.43%
+26,893
New +$1.21M
DNTH icon
42
Dianthus Therapeutics
DNTH
$5.77B
$1.3M 0.34%
+43,456
New +$945K
CRGX
43
DELISTED
CARGO Therapeutics
CRGX
$1.14M 0.3%
51,126
+24,251
+90% +$577K
CABA icon
44
PUT
Cabaletta Bio
CABA
$461M
$1.07M 0.28%
+500,000
New +$10.7M
KYTX icon
45
Kyverna Therapeutics
KYTX
$453M
$1.02M 0.27%
+41,000
New +$1.14M
XBI icon
46
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$876K 0.23%
+1,200,000
New +$111M
TARA icon
47
Protara Therapeutics
TARA
$230M
$675K 0.18%
+168,442
New +$544K
ARQT icon
48
PUT
Arcutis Biotherapeutics
ARQT
$3.56B
$516K 0.14%
+825,000
New +$6.16M
IMVT icon
49
CALL
Immunovant
IMVT
$8.27B
$319K 0.08%
+250,000
New +$9.12M
MRUS
50
PUT
DELISTED
Merus
MRUS
$213K 0.06%
+85,000
New +$3.45M
1
2
3 4 5

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Stempoint Capital held 101 positions worth $378M, up 0.93% from $375M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Stempoint Capital deployed $129M of net new capital in Q1 2024, opening 34 new positions and adding to 16 existing holdings. Its largest new stake was Tourmaline Bio: 274,219 shares worth $6.28M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Arcellx, an estimated $11M trimmed.

  • Stempoint Capital's largest Q1 2024 buy was Tourmaline Bio: 274,219 shares worth $6.28M.
  • Stempoint Capital added most to Autolus Therapeutics in Q1 2024, an estimated $15.7M increase.
  • Stempoint Capital's biggest Q1 2024 reduction was Arcellx, cutting an estimated $11M.
  • Stempoint Capital fully exited Protagonist Therapeutics in Q1 2024, selling an estimated $11.8M.
  • Stempoint Capital's ten largest holdings make up 57% of its $378M portfolio in Q1 2024.
  • Stempoint Capital opened 34 new positions and closed 39 in Q1 2024.
  • Stempoint Capital's portfolio value rose 0.93% quarter-over-quarter to $378M.

Based on Stempoint Capital's 13F filing for Q1 2024, filed 14 May 2024.